Prevalence and risk factors for thromboembolic complications in IBD patients by Schoepfer, A. et al.
P204
Small bowel mucosal healing and deep 
remission in patients with known small bowel 
Crohn's disease.
U. Kopylov*1, D. Yablecovitch2, A. Lahat2, S. Neuman2, N. Levhar2, 
E. Klang3, M.M. Amitai3, S. Ben-Horin2, R. Eliakim2
1Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 
2Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 
3Sheba Medical Center, Department of Diagnostic Imaging, Tel 
Hashomer, Israel
Background: Mucosal healing (MH) and deep remission (DR) 
are associated with improved long- and short-term outcomes in 
Crohn's disease. The vast majority of the available data pertains 
to colonic MH ***and DR, while the evidence regarding the 
prevalence and impact of small bowel mucosal healing (SBMH) 
is scarce.
The aims of the study were to evaluate the prevalence of active 
inflammation, SBMH and DR in small bowel Crohn's disease 
(SBCD) patients in clinical remission (CR) or clinically mild disease 
using biomarkers, video capsule endoscopy (VCE) and magnetic 
resonance enterography (MRE).
Methods: Patients with known SBCD in CR or with mild symp-
toms (CDAI<220) for at least 3  months were prospectively 
recruited and underwent MRE, followed by Agile patency capsule. 
If patency was ***proven, VCE was performed. The Lewis score 
(LS) was calculated for each tertile. C-reactive protein (CRP) and 
fecal calprotectin (FC) were evaluated for their association with 
clinical activity, MRE and VCE findings. Clinical remission was 
defined as CDAI < 150. FC >100  µg/g and CRP >5mg/ml were 
considered abnormal. SBMH was defined as LS< 135; significant 
SB inflammation was defined as LS >790. Biomarker remission 
(BR) was defined as a combination of CR (CDAI<150) and nor-
mal biomarkers. Deep remission (DR) was defined as a combina-
tion of BR and SBMH.
Results: Seventy nine patients were recruited and underwent 
MRE; 51 with proven patency underwent VCE studies. FC lev-
els were elevated in 47.5% of patients, CRP levels in 29.4% and 
either biomarker- in 56.5% of the cases. SBMH was observed in 
26% of the patients, and MRE did not demonstrate active disease 
in 23.7% of the patients. In patients with clinica and biomarker 
remission , SBMH was observed in 47.4% and MRE was normal 
in 56% of the patients. Deep remission was observed in 22.5% 
of the patients. The prevalence of deep remission was 50% in 
patients treated with anti-TNFs, whereas it was 20% in patients 
treated with thiopurines, 11% in patients not receiving any treat-
ment and 0% in patients treated with 5-aminosalycilates (p=0.045 
for treated vs not treated with anti-TNFs). There was a signifi-
cant correlation between normal FC levels and SBMH (r=0.48, 
p=0.001). CRP did not significantly correlate with SBMH (r=0.54 
p=0.1). The combination of both biomarkers did not improve the 
diagnostic accuracy.
Conclusions: SB inflammation is detected in the majority of CD 
patients in CR and BR. DR was achieved in 22.5% of the patients in 
clinical remission and was more frequent in patients ***treated with 
anti-TNFs. FC was significantly more accurate in prediction of MH 
than CRP. Our findings emphasize the true inflammatory burden in 
quiescent patients with SBCD.
UK and DY- equal contribution ; RE and SBH- equal contibution
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Ionizing radiation throughout the duration of 
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Background: Crohn's disease (CD) patients undergo many radiological 
studies employing ionizing radiation for diagnosis and management 
purposes. Our aim was to assess the total radiation exposure of our 
patients over the years, to estimate risk factors for exposure to high 
doses and to correlate radiation exposure to immunosuppression.
Methods: The cumulative effective dose of radiation (CEDR) was 
calculated multiplying the number of imaging studies by the effective 
dose of each exam. Radiation dose data was collected prospectively.
Results: Four hundred and fifty-one patients with CD (226 female) were 
followed during 11.0 years (IQR: 6.0-16.0), with 52.1% of the patients 
being B3-classified patients and 38.6% being steroid dependent. Thirty 
nine percent of the patients were under combo therapy and 41% had pre-
vious abdominal surgery. Sixteen percent were exposed to high radiation 
dose levels (CEDR>50 mSv) and 4% to CEDR>100 mSv. The mean CEDR 
between 26-35 years old was 12.539 mSv and a significant dose of radia-
tion (over 50 mSv) was achieved at a median age of 40 (IQR: 29.0-47.0).
Abdominal-pelvic computed tomography (CT) scan was the exami-
nation that contributed the most for CEDR.
High CEDR ( β value; 95% CI) were found for penetrating dis-
ease phenotype (22.785, 17.139;28.431), steroid resistance or 
dependence (8.860, 3.050;14.670), abdominal surgery (18.673, 
13.217;24.129), azathioprine (14.739, 6.875; 22.603) and anti-TNF 
therapy (17.141, 11.564; 22.716). Patients with penetrating pheno-
type (B3), previous surgery, azathioprine and anti-TNF α therapy 
were exposed earlier on the course of the disease to CEDR above 50 
mSv (p<0.001). The value of CEDR in the patients under immuno-
suppression mainly increased in the first year of immunosuppression.
Conclusions: Penetrating phenotype, abdominal surgery, steroid 
resistance or steroid dependence and treatment with anti-TNF α 
and azathioprine were predictive factors for high CEDR. It was also 
demonstrated that immunosuppression and anti-TNF α treatment 
were followed by a sustained increment of radiation exposure.
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Background: Inflammatory bowel disease (IBD) patients have an 
increased risk of venous thromboembolic complications (VTEC) 
such as deep vein thrombosis (DVT) and pulmonary embolism when 
compared to the non-IBD population. However, studies assessing 
VTEC prevalence in IBD as well as analyses of VTEC associated 
risk factors are scarce. We aimed to assess VTEC prevalence in IBD 
patients and to identify associated risk factors.
Methods: Data from patients enrolled in the Swiss IBD Cohort Study 
(SIBDCS) were analyzed. Since 2006 the SIBDCS collects data on a 
large sample of IBD patients from hospitals and private practices 
across Switzerland.
Results: A  total of 90/2284 (3.94%) IBD patients suffered from 
VTEC. Of these, 45/1324 (3.4% overall; 2.42% with DVT, 1.51% 
with PE) had CD, and 45/960 (4.7% overall; 3.23% with DVT, 
2.40% with PE) presented with UC.
In CD patients, median disease duration was 12 years in the VTEC 
group compared to 8 years in the CD group without VTEC (p=0.001). 
IBD-related intestinal surgery was more often performed in CD 
patients with VTEC compared to patients without VTEC (53.3% 
vs. 35.8%, p=0.016). No differences among the two groups were 
observed for perianal surgery (26.7% vs. 19.2%, p=0.216) or for 
disease location (p=0.596). UC-related intestinal surgery was more 
frequently encountered in the VTEC group compared to the one 
without VTEC (22.2% vs. 5.0%, p<0.001). Perianal surgery was not 
identified as risk factor for VTEC in CD patients (VTEC prevalence 
4.4% in CD patients having undergone perianal surgery vs. 2.0% 
VTEC prevalence in CD patients not having undergone perianal sur-
gery, p=0.240). UC patients with VTEC were found to suffer more 
frequently from pancolitis when compared to UC patients without 
VTEC (53.3% vs 40.3%, p=0.003). IBD treatment, including immu-
nomodulators and anti-TNF agents, was used in similar frequencies 
in CD and UC patients with and without VTEC. Ciclosporin use 
was more prevalent in UC patients group with VTEC (15.6% vs. 
6.0%, p=0.021). Logistic regression modeling found no significant 
association of VTEC with the following factors: age, gender, use of 
oral contraception, body mass index, smoking status, age at time of 
IBD diagnosis, and IBD family history.
Conclusions: IBD is associated with an important number of VTEC. 
VTEC were more prevalent in UC patients compared to CD patients. 
Intestinal surgery is a risk factor for VTEC in both UC and CD patients. 
Disease duration was identified as risk factor for VTEC in CD patients 
whereas pancolitis was significantly associated with VTEC in UC patients.
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Background: Disease recurrence after Crohn's disease resection 
occurs in up to up to 80% of patients, with two thirds ultimately 
requiring further surgery. Although clinical risk factors help in 
assessing the risk of relapse, a test that identifies patients at higher 
risk of recurrence would be clinically valuable. We investigated the 
value of serological antimicrobial antibodies to predict disease recur-
rence after surgery in a large prospective cohort of patients.
Methods: 171 patients had 525 samples tested peri-operatively, 
and 6, 12 and 18 months post-operatively as part of a structured 
study ("POCER") designed to diminish post-operative recurrence. 
Two-thirds of patients underwent colonoscopy at 6 months and all 
underwent colonoscopy at 18  months post-operatively. Serologic 
markers (ANCA, pANCA, ASCA IgA/IgG, anti-OmpC, anti-CBir1, 
anti-A4-Fla2, anti-Fla-X) were tested at each time point. Univariate 
analysis was performed for each (positive/negative) at all time points 
for endoscopic recurrence (Rutgeert's score ≥i2). Antibody titre was 
investigated using quartile sum score (QSS) method (range 7-28) and 
logistic regression analysis.
Results: Patients with recurrence at 18 months were more likely to 
be positive for anti-Fla-X than those without recurrence, when meas-
ured at baseline (64% v 45%; P=0.049), 6 months (65% v 43%, 
P=0.021) and 18 months (53% v 33%, P=0.038) post operatively. 
Patients negative for anti-Fla-X at 6  months had a lower risk of 
recurrence at 18  months (OR 0.38, 95%CI 0.17-0.84, P=0.018), 
when adjusted for age, gender, disease behaviour and smoking. 
A negative ANCA titre at 6 months was associated with recurrence 
at 6 months (ANCA -ve v +ve: recurrence 87% v 13%, P=0.002). 
Adjusted for baseline characteristics (age, gender disease location, 
smoking, pANCA) the total antibody titre for all antibodies com-
bined was not predictive of endoscopic recurrence at 6 or 18 months.
Conclusions: The presence of the serological antibody anti-Fla-X 
identifies patients at higher risk of developing early disease recur-
rence, while the presence of positive ANCA predicts patients at 
lower risk of post-operative recurrence. Fla-X is an immunogenic 
bacterial antigen, arising from subunits of bacterial flagella (flagellin) 
from Clostridium subphylum cluster XIVa. Serologic screening of 
patients prior to surgery may assist in selecting patients at elevated 
risk of post-operative recurrence. The role of Fla-X in relation to 
microbiota that may be linked to recurrence requires evaluation.
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Background: Biological and thiopurine drugs are these days consid-
ered to be first line long-term treatment for severe or 5-ASA non-
responding cases of IBD. Treatment strategies can be either single 
or combination therapy. The monitoring of these treatments tend to 
vary depending on which treatment strategy is chosen. Patients with 
biological treatment as either mono- or combination therapy tend to 
be more frequently monitored, but the frequency and extent of mon-
itoring varies between different IBD clinics. At Danderyd Hospital, 
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